Analysts: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Could Go to 20.00

Analysts are weighing in on how Halozyme Therapeutics, Inc. (NASDAQ:HALO) , might perform in the near term. Wall Street analysts have a  assessment of the stock, with a mean rating of 2.0. The stock is rated as buy by 4 analysts, with 3 outperform and 0 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 8.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.27 a share, which would compare with $0.02 in the same quarter last year. They have a high estimate of $-0.15 and a low estimate of $-0.31. Revenue for the period is expected to total nearly $29.86M from $43.38M the year-ago period.

For the full year, 8.00 Wall Street analysts forecast this company would deliver earnings of -1.03 per share, with a high estimate of $-0.74 and a low estimate of $-1.26. It had reported earnings per share of $-0.25 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $138.74M versus 135.06M in the preceding year.

Among the 7 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for HALO is $14.54 but some analysts are projecting the price to go as high as $20.00. If the optimistic analysts are correct, that represents a 123 percent upside potential from the recent closing price of $8.97. Some sell-side analysts, particularly the bearish ones, have called for $6.75 price targets on shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) .

In the last reported results, the company reported earnings of $0.02 per share, while analysts were calling for share earnings of $-0.09. It was an earnings surprise of 122.20%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The companys products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and other cancers in combination with various cancer therapies. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd., Hoffmann-La Roche, Inc., Baxalta US Inc., Baxalta GmbH, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., and Eli Lilly and Company. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.